Friday December 05 2008 | Biotechnology feed | All feeds
|
|
Friday December 05 2008 | Biotechnology feed | All feeds
|
|
|
Inpharmatica secures ADME service agreement with Ionix Pharmaceuticals
London and Cambridge, UK, August
7, 2003 -- Inpharmatica Ltd, a leading informatics-driven drug discovery
company, today announced that it has entered into a non-exclusive ADME service
agreement with Ionix Pharmaceuticals Ltd, the European analgesic drug
discovery company. This follows rapidly upon the announcement by Inpharmatica
in June of plans to acquire research capabilities in ADME (absorption,
distribution, metabolism and excretion) through the purchase of labs,
licensing of intellectual property and employment of an experienced ADME team.
Financial terms of the Ionix transaction were not disclosed.
Under the terms of the agreement,
Inpharmatica and Ionix will collaborate on the generation of in vitro
and pharmacokinetic ADME data for certain Ionix product development programmes.
Commenting on the announcement, Dr Mike Tarbit, Senior Vice President - Preclinical R&D at Inpharmatica, said: "This agreement demonstrates the value of Inpharmatica's unique combination of experience in lead optimization, application of its in silico tools, and ADME laboratory facilities in Cambridge. Inpharmatica's service means that biotech companies like Ionix can focus their internal resources on their novel approaches to drug discovery, whilst accessing state-of-the-art lead optimization support." Commenting on the announcement, Andrew Sandham, Chief Executive Officer of Ionix Pharmaceuticals, said: "Inpharmatica has provided Ionix with a flexible approach to providing high quality ADME data to support progression of our compounds through lead optimization. By working with Inpharmatica, we have been able to use their expertise to accelerate the development of our preclinical product candidates." About Ionix Pharmaceuticals: www.ionixpharma.com Ionix Pharmaceuticals, based in Cambridge UK, is a leader in the discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Using proprietary drug targets and state-of the-art chemistry, the company is developing medicines that are designed to alleviate pain associated with trauma, operative procedures, and debilitating diseases such as arthritis, diabetes and multiple sclerosis. Ionix Pharmaceuticals is a privately held company and was founded in 2001.
About Inpharmatica:
www.inpharmatica.com
Inpharmatica Ltd is a leading
informatics-driven drug discovery company. Inpharmatica's flagship technology
platform is PharmaCarta[TM], a computational chemogenomics system. It links
genomic and proteomic space with chemistry and provides a unique approach to
hit identification and lead generation and optimization for druggable targets.
Biopendium[TM] is an integral part of PharmaCarta[TM] that is also available
to clients as a stand alone product. Inpharmatica's platform utilizes the
massive computing power of the company's 2,500- processor compute farm, one of
the largest in the world.
Founded in 1998, Inpharmatica's
technology is based on research from Professor Janet Thornton's group at
University College London. Employing approximately 100 staff, Inpharmatica is
headquartered in London where it has its own in-house laboratory facilities.
These laboratory facilities provide experimental validation of in silico
discoveries, enabling Inpharmatica (and its strategic partners) to advance
novel drug targets identified through its application of PharmaCarta[TM] and
to develop novel drugs against those targets. The company's ADME and chemistry
facilities are located on the Cambridge Science Park and provide support for
the company's internal discovery programs as well as contract ADME services.
Inpharmatica operates a hybrid business model with four distinct components: i. Internal discovery programs for long-term value generation;
ii. Application of PharmaCarta[TM]
to research programs of collaborators, generating mid-term value through
research payments, milestone payments and royalties;
iii. Biopendium[TM] licensing to
generate near-term revenues; and
iv. ADME Optimization to generate
near-term revenues and extend the capabilities of PharmaCarta[TM].
These components are outlined further below: Internal Drug Discovery is focused upon discovering, validating and finding leads against highly druggable targets mined from the human genome, and has resulted in the company filing patents over more than 200 novel proteins to date. The company's lead discovery program is focused upon the development of 16 novel Nuclear Receptors ("NR's"). NR's are a family of proteins widely considered to be both druggable and of high therapeutic interest. Drugs targeted against NR's generate more than $10bn in sales annually. Inpharmatica's novel NR's represent a more than a 30% increase on those identified in the public domain.
PharmaCarta[TM] is the company's
knowledge-based chemogenomics technology platform which drives the discovery
process from gene to drug candidate. Inpharmatica applies PharmaCarta[TM] both
in collaboration with third parties and for internal drug discovery. The
company concluded its first PharmaCarta[TM] collaboration, for the
identification of novel protein therapeutics, with Serono in July 2001, a
collaboration that was further expanded in January 2003. Since then, the
company has concluded further PharmaCarta[TM] collaborations with Chiron and
Galapagos.
Biopendium[TM] is the company's
proteome annotation resource, accessed by partners through commercial license.
It is the world's most comprehensive annotation resource; enabling rapid high
throughput annotation of large datasets for target prioritization, target
mining and microarray analysis. Inpharmatica's non-exclusive subscription
collaborators include Pfizer, Genentech, Serono, Daiichi and Riken.
Inpharmatica also has a joint venture with Celera to develop a special edition
of the Biopendium[TM] that incorporates Celera's proprietary genomic data (Celera
Edition Biopendium[TM]).
ADME Optimization is the latest
offering from Inpharmatica, providing a further enhancement of PharmaCarta[TM],
and so moving the company's drug discovery capabilities downstream.
Inpharmatica makes the in silico, in vitro and Lead Optimization
experience of its experienced ADME team available to third parties, such as
other biotechnology and pharmaceutical companies, on a fee for service basis.
This team is based on the Cambridge Science Park.
For information about
Inpharmatica:
Andrew Lloyd Andrew Lloyd & Associates +44 1273 675100 For information about Ionix Pharmaceuticals:
Andrew Sandham
+44 1223 433 733
|
|
|
